ArticleScientific data2025
Estimating the deferred value of pathogen genomic data for secondary use.
Article in Scientific data, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Enriching Public Pathogen Genomic Records With Patient Metadata: Quantitative Study and Exploratory Case Analysis.JMIR bioinformatics and biotechnology · 2026Article
- Antibiotic-Specific Genotype-Phenotype Concordance and Cross-Database Interoperability in PublicInternational journal of molecular sciences · 2026Article
- A Metadata-Driven Framework for Strengthening Pathogen Genomics Lessons from SARS-CoV-2.medRxiv : the preprint server for health sciences · 2025Article
- Large language models for biological sequence analysis in infectious disease research.Biosafety and health · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The COVID-19 pandemic has illuminated the utility of pathogen genomics and highlighted roadblocks to international data sharing. This article describes the deferred value of pathogen genomics data for secondary use using a set of 10,110 assembled genomes of Vibrio cholerae shared via international repositories between 2010 and 2024 as an illustrative representation of a pandemic disease. Trends in the quality, representativeness, and timeliness of data sharing as well as the increasing role of microbiology services as genomic data providers resulting from gradually improving access to sequencing technologies in countries with a high burden of disease were identified. The deferred value of individual and aggregated genomic data was tracked over time and mapped to geographical hot spots of cholera. The time lag between the collection of the samples for V. cholerae cultures and the submission of the genome to an international database remained eight years on average. The data value assessment described here paves the way for the international mobilization of quality microbial genomic data for global health and knowledge discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.